Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to monotherapy by leveraging synergistic mechanisms of both incretin hormones.
Tirzepatide is a weekly injection that mimics two gut hormones (GIP and GLP-1) to improve blood sugar control and promote significant weight loss. It is a newer option for T2DM and obesity, offering benefits beyond what single-hormone therapies provide.
GoodSupportsHIGH confidence
Tirzepatide is a unimolecular dual agonist that acts as an analogue of gastric inhibitory polypeptide (GIP) and as a receptor agonist for glucagon-like peptide 1 (GLP-1).
Why this rating
Supported by clinical trials (SURMOUNT-1, SURPASS-CVOT) cited in the review.
Source
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Alfredo Caturano et al. · Biomedicines · 2024
DOI 10.3390/biomedicines12092039
narrative_reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors lower blood glucose by inhibiting renal glucose reabsorption, resulting in glucosuria, with efficacy dependent on maintaining a filtered glucose load above 80g/day.Good
- GLP-1 Receptor Agonists (GLP-1RAs) improve glycemic control and promote weight loss by enhancing glucose-dependent insulin secretion, inhibiting glucagon, slowing gastric emptying, and reducing appetite via central nervous system pathways.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →